Creatures Worth Meeting

[SOFIA] Okay, so here's a question I want to start with. How many microbial species do you think humans have actually learned to grow and genetically manipulate in a lab?

[DANIEL] Hm. If you mean really domesticated — electroporate it, transform it, swap genes in and out reliably — the honest answer is a tiny fraction. A handful of workhorses.

[SOFIA] A handful! E. coli, baker's yeast, Bacillus, maybe Pseudomonas if you're feeling adventurous. And meanwhile the actual diversity of life out there is just — staggering. The ocean alone is full of organisms doing chemistry we can't even imagine.

[DANIEL] And the reason we keep reaching for the same few is practical. A model organism isn't model because it's special biologically. It's model because somebody, decades ago, figured out how to get DNA into it, select transformants, and grow it on a plate. Everything downstream depends on that.

[SOFIA] Right, so the whole segment today is about the creatures worth meeting — the organisms that got left out. The psychrophile living in sea ice at temperatures that should shut metabolism down. The dinoflagellate nobody could transform. And the growing push to bring those into the fold as engineerable chassis.

[DANIEL] And I'd flag the vocabulary up front, because it trips people. For bacteria and archaea, getting DNA in is transformation — or conjugation, or electroporation depending on the method. Not transfection. Transfection is a eukaryotic-cell word. If a bacterial paper says transfection, someone slipped.

[SOFIA] The terms matter because the methods are genuinely different physical problems. A diatom has a silica frustule. A dinoflagellate has this enormous, weird genome. Each one is its own engineering puzzle.

[DANIEL] So the problem statement is: intractability. These organisms resist the standard toolkit. No reliable way in, no selectable markers that work, no plasmid that replicates in them, no promoters you can trust to fire. And that's the through-line — the arc of this field is people chipping away at intractability, species by species.

[SOFIA] Let's trace it. I'd start the story in 2020, with the Fatma review on domesticating non-model microbes. This is the manifesto moment, right? The argument that non-model bugs — actinobacteria, cyanobacteria, non-conventional yeasts, fungi — can be real cell factories for chemicals and fuels and materials, but only if you build organism-specific genetic tools first.

[DANIEL] And CRISPR is the lever they point to. Because the beautiful thing about CRISPR relative to older genome editing is that it's reprogrammable. You're not re-engineering a protein for every target, you're swapping a guide RNA. So in principle you can port the same editing logic across very different organisms.

[SOFIA] In principle.

[DANIEL] In principle. The review is honest that intrinsic intractability is the wall. CRISPR doesn't magically get itself into a cell that won't take up DNA. You still have to solve delivery first.

[SOFIA] Which is exactly why the second 2020 paper is, to me, the real turning point. The EMS initiative — marine protists. And the scale of this thing is wild. Forty-one research groups, a hundred and thirteen authors, funded by the Moore Foundation, all coordinated to systematically test transformation across thirty-nine marine protist species.

[DANIEL] And spanning all the eukaryotic supergroups, which is the part I respect. This isn't cherry-picking one convenient alga. They deliberately sampled across the whole eukaryotic tree.

[SOFIA] Okay, this is the good stuff — because what came out of it wasn't just success stories. Thirteen first-ever transformation protocols. The first nuclear transformation of a dinoflagellate. The first transformation of an Antarctic diatom. Eight more organisms pushed to advanced protocols.

[DANIEL] But here's what makes it good science rather than a trophy case. They published the failures. They distilled the whole collective effort — what worked, what didn't — into a synthetic transformation roadmap. That's the opposite of the usual publication bias, where you only ever see the wins.

[SOFIA] And that matters because the next lab that wants to crack a new protist isn't starting from zero. They've got a decision tree. Try electroporation with these parameters, these selectable markers, this promoter architecture.

[DANIEL] It converts transformation from folklore into something closer to a protocol. That's the conceptual shift. You asked where the field turned — it turned there, from heroic one-off efforts to a shared, documented method space.

[SOFIA] So then you get the 2024 wave, where the tools themselves get more modular and portable. The In- and Out-Cloning paper, de Vries and colleagues. This is Golden Gate assembly territory — SapI with three-nucleotide overhangs giving you scarless, MoClo-compatible transcription units.

[DANIEL] Let me unpack that for anyone outside cloning. MoClo — modular cloning — is a standardized Lego system. You have defined parts, promoters, coding sequences, terminators, with defined junctions, and you snap them together in one pot. The problem has always been the acceptor plasmid — the backbone you assemble into — has to be built for your specific organism's origin of replication and markers.

[SOFIA] And Out-Cloning generates those organism-specific acceptor plasmids on demand, from modular parts. So you're not locked into E. coli backbones. You can build the vector that fits your weird chassis.

[DANIEL] Which connects straight back to the EMS problem. A roadmap tells you what conditions to try. Modular, organism-agnostic cloning gives you the parts to actually build with once you're in.

[SOFIA] Then the Pseudomonas work — Roghair Stroud and colleagues, the P. alloputida KT2440 CRISPRi platform. And this one I love because it moves out of the flask and into the dirt.

[DANIEL] CRISPRi — that's dCas9, catalytically dead Cas9. It doesn't cut, it just parks on DNA and blocks transcription. Reversible repression instead of permanent edits. Here they put it under an XylS/Pm promoter, integrated it into the chromosome via mini-Tn7 — a transposon that drops into a defined single site — and ran it with a pSEVA sgRNA suite.

[SOFIA] And the headline is the first in-situ gene repression in the rhizosphere. In the root zone. They actually knocked down pyoverdine — that's the siderophore, the iron-scavenging molecule Pseudomonas uses to outcompete its neighbors for iron — and disabled that competitive edge, in place.

[DANIEL] That's a real escalation. Doing CRISPRi in a controlled culture is one thing. Doing it in the messy, crowded rhizosphere and getting a measurable phenotype — that's the tool surviving contact with the real environment.

[SOFIA] And the last two papers point at the frontier: extremophiles. The polyextremophile engineering framework boils adaptation down to four proximal stress mechanisms — reactive oxygen species, covalent damage, protein fold destabilization, and membrane fluidity.

[DANIEL] And the useful claim is that those four let you predict which combinations of stresses are synergistic versus antagonistic. So instead of guessing, you rationally design a chassis for, say, space-based in-situ resource utilization, or industrial biomanufacturing at high temperature and high salt.

[SOFIA] And then Jody Deming's piece on Colwellia — the psychrophiles in sea ice that just keep functioning below the temperatures we thought metabolism allowed.

[DANIEL] Which I'd hold up as the honest counterweight. Our predictive frameworks say there are limits. Colwellia exceeds them. So the organisms are still ahead of the theory — there's biology in that ice we don't understand yet.

[SOFIA] Which is the perfect place to land. The arc goes from "we can only engineer a handful of bugs," to roadmaps, to portable modular tools, to editing in soil — and the destination is these extreme organisms that still outrun our models.

[DANIEL] Meet the creatures first. The theory catches up later.

[SOFIA] That's our Arc for today. Stay with us.